RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma. 26 Aug, 2022 | 13:09h | UTC Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma – Journal of Clinical Oncology